TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15054430
Drug: Five portions
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five portions (750 g) of fruits and vegetables daily
Study: 9695991
Drug: Ursodeoxycholate (UDC)
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholate (UDC) treatment
Study: 8016587
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy laser (LEL) treatment
Study: 2699615
Drug: Flatulence treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flatulence treatment
Study: 769971
Drug: DTIC (NSC-45388)
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DTIC (NSC-45388) with other drugs
Study: 769971
Drug: DTIC (NSC-45388)
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DTIC (NSC-45388) as an adjuvant to standard surgical therapy
Study: 26972526
Drug: Movement imitation
Normalized name: BERGAMOT,IMITATION
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement imitation therapy (experimental group)
Study: 20413299
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment in KRAS wild type patients
Study: 20413299
Drug: No cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No cetuximab treatment in KRAS wild type patients (control group)
Study: 16135348
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus fentanyl (BF) 3 microg/mL
Study: 10065895
Drug: Heparin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (50 IU/kg)
Study: 2126738
Drug: Leuprolide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide + Flutamide (L + F)
Study: 2126738
Drug: Leuprolide (L)
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide (L) alone
Study: 7021263
Drug: Amoxycillin administered
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin administered twice daily (50 mg/kg body-weight/day)
Study: 7021263
Drug: Amoxycillin administered
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin administered four times daily (50 mg/kg body-weight/day)
Study: 31398066
Drug: Facemask therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask therapy (FM group)
Study: 31398066
Drug: Facemask therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask therapy with a miniscrew (FM+MS group)
Study: 24521647
Drug: Biapenem (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (300 mg every 12 h)
Study: 11743708
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (active treatment)
Study: 11743708
Drug: Traditional symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional symptom alleviation (passive treatment)
Study: 9924711
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally once daily for 3 days (n = 150)
Study: 9924711
Drug: Co-amoxiclav 625
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 625 mg orally three times daily for 5-10 days (n = 153)
Study: 9419764
Drug: Estrogen alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen alone (0.625 mg conjugated equine estrogen for 6 months)
Study: 9419764
Drug: Estrogen with
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen with progestin (0.625 mg conjugated equine estrogen with 10 mg medroxyprogesterone acetate for 10 days each month for 6 months)
Study: 9419764
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test (ITT) and frequently sampled intravenous glucose tolerance test (FSIVGTT)
Study: 29661378
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside 0.5 μg kg-1 min-1 during RS-ketamine infusion
Study: 29661378
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during RS-ketamine infusion
Study: 29661378
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside 0.5 μg kg-1 min-1 during esketamine infusion
Study: 29661378
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during esketamine infusion
Study: 14653298
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and disk treatment
Study: 10523001
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH treatment (0.15 IU/kg x day) for 1 week
Study: 8619701
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (600 mg in divided doses 12 hours before operation)
Study: 16829774
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation interventions for smokers addicted to illicit drugs, alcohol, or both
Study: 11308434
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort extract (900 mg/d for 4 weeks, increased to 1200 mg/d if no adequate response)
Study: 9257200
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg i.v. for dose 1, placebo for dose 2, ketorolac 30 mg i.v. for doses 3, 4, and 5 (Group 2)
Study: 9257200
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg i.v. for dose 1, ketorolac 30 mg i.v. for doses 3, 4, and 5 (Group 1)
Study: 9257200
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for all doses (Group 3)
Study: 8305166
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitrendipine once daily for 12 weeks
Study: 8305166
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cilazapril once daily for 12 weeks
Study: 22459388
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 units of oral vitamin D3)
Study: 8997575
Drug: Maxitrol (neomycin
Normalized name: Maxitrol (neomycin 3.5 MG / polymyxin b 10,000 UNT / dexAMETHasone 1 MG) per GM Ophthalmic Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxitrol (neomycin sulphate 3500 IU/mL, polymyxin‐B sulphate 6000 IU/mL with dexamethasone 0.1%)
Study: 1617932
Drug: cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefaclor 250 mg three times daily
Study: 26486011
Drug: Dydrogesterone 20
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 20 mg twice daily (n=96)
Study: 26486011
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone 400 mg twice daily (n=114)
Study: 15259296
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (CRO) 10 mg, administered twice in the first 24 hours postoperatively
Study: 15259296
Drug: Intravenous tramadol/metamizol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol/metamizol (TM) 100 mg tramadol + 1 g metamizol every 4 h for 24 h, placebo tablet at recovery
Study: 12099518
Drug: Cyclosporine microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine microemulsion absorption profiling (AUC)
Study: 12099518
Drug: Conventional trough-level
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional trough-level drug monitoring (C0)
Study: 12099518
Drug: C2 values
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 values above approximately 1500 microg/L by day 3 post-transplant
Study: 10233191
Drug: PAM (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAM (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s.)
Study: 10233191
Drug: PCM (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCM (pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s.)
Study: 10233191
Drug: PAC (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d.)
Study: 2112516
Drug: Nitroglycerin (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.8 mg)
Study: 623044
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids alone (1 g/kg per day)
Study: 623044
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids plus 100 g glucose daily
Study: 26428452
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine information statement (VIS)
Study: 20709992
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg tablet once daily)
Study: 19040336
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg, three times daily for 6 months (O group)
Study: 19040336
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day for 6 months (E group)
Study: 19040336
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg and Ezetimibe 10 mg/day for 6 months (OE group)
Study: 15867169
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin and irbesartan
Study: 9493502
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at 3 mg/kg bodyweight
Study: 9493502
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at 1 mg/kg bodyweight
Study: 28619
Drug: Benorylate (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benorylate (6 g/day)
Study: 28618737
Drug: Artcure Diffusional
Normalized name: LUNG DIFFUSION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artcure Diffusional Patch
Study: 28618737
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal diffusional patch
Study: 19589242
Drug: Simvastatin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (6 months treatment)
Study: 19589242
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy alone (control group)
Study: 11784832
Drug: Detailed cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed cognitive assessment and treatment programme
Study: 9701525
Drug: Eradication regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication regimens based on omeprazole plus antibiotics and bismuth plus antibiotics
Study: 25075
Drug: Acebutolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (300 mg)
Study: 1234486
Drug: Practolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (400 mg)
Study: 30859680
Drug: Standard omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard omeprazole doses
Study: 30859680
Drug: Personalized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized therapy based on CYP2C19 polymorphism
Study: 28371078
Drug: 10% D/DC-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% D/DC-containing cream
Study: 28371078
Drug: 20% D/DC-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% D/DC-containing cream
Study: 26460279
Drug: Prasugrel (loading/maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (loading/maintenance dose: 20/3.75 mg)
Study: 26460279
Drug: Clopidogrel (loading/maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading/maintenance dose: 300/75 mg)
Study: 23181738
Drug: Ingesting all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingesting all prescribed once-a-day hypertension medications upon awakening
Study: 23181738
Drug: Bedtime hypertension
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime hypertension treatment
Study: 17917685
Drug: Immediate Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Sequential Cataract Surgery (ISCS)
Study: 17917685
Drug: Delayed Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Sequential Cataract Surgery (DSCS)
Study: 11571822
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (impulse magnetic-field therapy, 16 Hz, 5 microTs)
Study: 9784038
Drug: Oral Imedeen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Imedeen
Study: 28719008
Drug: Gemigliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin (50 mg)
Study: 22943969
Drug: Heated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 2 hours
Study: 22943969
Drug: Heated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Study: 22943969
Drug: Heated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 12 hours
Study: 22943969
Drug: Unheated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unheated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Study: 22943969
Drug: Heated patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg)
Study: 21095263
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus Simvastatin 20 mg daily
Study: 18692886
Drug: Levalbuterol HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol HFA MDI (45 microg per dose)
Study: 18692886
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol HFA MDI (90 microg per dose)
Study: 15960560
Drug: Duloxetine (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (80-120 mg/day)
Study: 12610044
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg o.d. for >26 weeks)
Study: 7669958
Drug: Low loading
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low loading dose of milrinone (20 micrograms/kg during 15 minutes)
Study: 7669958
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading dose of milrinone (40 micrograms/kg during 15 minutes)
Study: 6770673
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day for 10 days to 3 weeks)
Study: 6770673
Drug: Amoxicillin trihydrate
Normalized name: Amoxicillin Trihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin trihydrate (40 mg/kg/day for 10 days to 3 weeks)
Study: 6770673
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium (20 mg/kg/day for 10 days)
Study: 28240983
Drug: Digits-in-noise (DIN)
Normalized name: hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digits-in-noise (DIN) test administered via personal computer
Study: 23094264
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B Advantage)
Study: 23094264
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B CrossAction)
Study: 23094264
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B ShinyClean)
Study: 19823185
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg dairy and non-dairy calcium
Study: 19823185
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dairy and non-dairy calcium
Study: 18171957
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (Group 2)
Study: 16120776
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with expected analgesic properties
Study: 12590855
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg, 7-day regimen)
Study: 12590855
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg, 10-day regimen)
Study: 8452170
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg every 8 hours for 7 days
Study: 3540918
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) administered twice daily
Study: 3540918
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) administered four times daily
Study: 22024905
Drug: High-dose supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supervised strengthening exercise with spinal manipulation (ET + SMT)
Study: 22024905
Drug: High-dose supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supervised strengthening exercise (ET)
Study: 19606689
Drug: Johrei treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johrei treatment (18 sessions over 6 weeks)
Study: 20424424
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 43)
Study: 15720887
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of nevirapine (NVP)
Study: 15720887
Drug: NVP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP with zidovudine (ZDV) twice daily for a week
Study: 6214377
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin 1.5 percent solution (Staticin solution)
Study: 6214377
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg twice a day)
Study: 30235940
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) adherence
Study: 31488063
Drug: Concurrent ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent ART and tuberculosis treatment
Study: 31488063
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a second line ART regimen with higher pill burden
Study: 28369381
Drug: Kaletra® 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaletra® 400/100 mg plus tenofovir disoproxil/emtricitabine (200/245 mg) once daily
Study: 1724233
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (disopyramide and mexiletine)
Study: 1724233
Drug: Disopyramide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide and mexiletine combination
Study: 31002475
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg once a day (QD) for 3 months (Group A)
Study: 31002475
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg twice a day (BID) for 3 months (Group B)
Study: 31002475
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg BID plus mosapride citrate 5 mg three times a day (TID) for 3 months (Group C)
Study: 29345213
Drug: Matcha green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matcha green tea drinks (1 g of Matcha premium grade; OMGTea Ltd., Brighton, UK) consumed the day before and 2 hours before the walk
Study: 21791662
Drug: Danoprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir (400 mg, 600 mg, and 900 mg twice daily) in combination with pegylated interferon α‐2a (180 μg once weekly) and ribavirin (1000‐1200 mg/day)
Study: 21791662
Drug: Danoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir (100 mg, 200 mg, and 300 mg 3 times daily) in combination with pegylated interferon α‐2a and ribavirin
Study: 21791662
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with standard of care
Study: 9642510
Drug: MMF 3
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3 g/d with low cyclosporine and steroid doses
Study: 8033372
Drug: Salbutamol (SAL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (SAL, 0.08 mg/kg orally)
Study: 8033372
Drug: Arginine (ARG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (ARG, 0.5 g/kg i.v.)
Study: 8033372
Drug: Pyridostigmine (PD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD, 120 mg orally)